Reports & resources developed through the Value & Access Initiative:
**NEW** What Do Value & Access Really Mean? A Landscape Report on Stakeholder Perspectives – reports on differences in how the “6 Ps”—patients, providers, payers, purchasers, public health, and pharma/biotech—view these issues. It also finds an area of common ground that may enable stakeholders to work together to solve ever-rising healthcare costs and clashes over cost-containment measures. The report documents changes in stakeholders’ views over the last 3 years and a shift from opposition to collaboration on certain issues related to healthcare access and affordability.
SHARED Decision Making Tool for Patients & Providers
Worksheets designed for patients and providers to use in role modeling conversation on discussing FH (familial hypercholesterolemia) and Statin-Related Side Effects, and Atherosclerotic Cardiovascular Disease (ASCVD) treatment options, concerns, preferences, and goals created in collaboration with the FH Foundation, National Lipid Association, and American Pharmacists Association Foundation.
A checklist modeling processes for P&T Committees to consider when managing the formulary system in making equitable coverage decisions, focusing on evidence-based processes to select and promote treatments offering the best therapeutic outcomes, while minimizing potential risks and costs to patients.
The Value & Access initiative brings together diverse decision-makers from varied stakeholder groups (patients, providers, payers, purchasers, public health and pharma/biotech) to engage in discussion and solution-oriented activities on value and access issues related to cardiovascular health. This white paper outlines accomplishments to-date, and the evolution of the initiative.
Reveals how patients, providers, payers, public health and industry view the value of therapies and what access means to them.
Value Frameworks developed by other organizations – useful resources in the discussion of value and access.